Quoin Pharmaceuticals’ QRX003 Gains Orphan Drug Status

The latest announcement is out from Quoin Pharmaceuticals ( (QNRX) ).

On May 20, 2025, Quoin Pharmaceuticals announced that the European Medicines Agency granted Orphan Drug Designation for its lead product, QRX003, for treating Netherton Syndrome. This designation provides benefits like market exclusivity for 10 years upon approval, scientific advice, and fee reductions. QRX003 is in late-stage clinical trials and shows promising results in treating Netherton Syndrome, a condition with no approved therapies, highlighting Quoin’s progress in addressing unmet medical needs.

The most recent analyst rating on (QNRX) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Spark’s Take on QNRX Stock

According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.

Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.

To see Spark’s full report on QNRX stock, click here.

More about Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. The company’s innovative pipeline includes four products targeting conditions such as Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and others.

Average Trading Volume: 371,543

Technical Sentiment Signal: Strong Sell

Current Market Cap: $4.7M

For detailed information about QNRX stock, go to TipRanks’ Stock Analysis page.